News Search Results
Dec 16, 2025, 08:00 ET TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B financing in support of their Phase 2 trial of AV078, a first-in-class CNS-penetrant selective mTORC1 inhibitor in tuberous sclerosis complex (TSC).
More news about: TSC Alliance
Dec 16, 2025, 08:00 ET Nota AI Optimization Technology Drives Traffic Innovation in Africa, Following Success in the Middle East
accelerates expansion from Middle East to AfricaSigns technology supply contract with HANIL STM for the Nairobi ITS Project led by LG CNSSEOUL, South Korea, Dec. 16, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu
More news about: Nota AI
Dec 16, 2025, 02:00 ET Nota AI Optimization Technology Drives Traffic Innovation in Africa, Following Success in the Middle East
accelerates expansion from Middle East to AfricaSigns technology supply contract with HANIL STM for the Nairobi ITS Project led by LG CNSSEOUL, South Korea, Dec. 16, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu
More news about: Nota AI
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
orally at the 2025 ASCO Annual Meeting [1]. The results showed a CNS-ORR of 67.6%, a central nervous system clinical benefit rate (CNS-CBR) of 88.2%, and a median central nervous system progression-free survival (CNS-PFS) of 15 months. The results of another Phase II clinical study of utidelone
More news about: Biostar Pharma, Inc.
Dec 12, 2025, 08:35 ET Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Dec 11, 2025, 07:00 ET NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
medicinal chemistry aimed at developing first- or best-in-class treatments for major CNS disorders, from ALS to narcolepsy."The patent covers a broad family of compounds with potential applications in multiple CNS-related conditions, including narcolepsy, where dysregulation of orexin signalling
More news about: NewcelX Ltd.
Dec 11, 2025, 02:00 ET Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
medicine and Adasuve®, will be eliminated, delivering immediate cost savings and enhancing overall deal economics.In addition, two promising CNS pipeline assets targeting Parkinson's disease and Cyclic Vomiting Syndrome (CVS), both at Phase 2 clinical stage, will be integrated into the Company's
More news about: Lee's Pharmaceutical Holdings Limited
Dec 11, 2025, 02:00 ET Lee's Pharmaceutical Holdings Limited acquiert la plateforme et les actifs de Staccato® One Breath Technology®, renforçant ainsi l'expansion de son pipeline et faisant progresser son partenariat mondial avec UCB grâce aux droits acquis
permettra de réaliser des économies immédiates et d'améliorer l'économie globale de l'opération.En outre, deux actifs prometteurs du pipeline CNS ciblant la maladie de Parkinson et le syndrome des vomissements cycliques (SVC), tous deux au stade clinique de phase 2, seront intégrés au portefeuille
More news about: Lee's Pharmaceutical Holdings Limited
Dec 10, 2025, 15:30 ET Connected Nation's BEAD Tracker provides details for the nearly 4M locations to get broadband using $20B in federal funds
of high-speed internet both in your area and nationally. That includes tracking the technology type, providers awarded funds, and much more." CN's BEAD Tracker (
More news about: Connected Nation
Dec 10, 2025, 09:43 ET Cohen & Steers Launches Infrastructure Opportunities and Short Duration Preferred Securities Active ETFs
NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) is adding to its suite of actively managed exchange-traded funds (ETFs) with the launch of two new strategies: the Cohen & Steers Infrastructure
More news about: Cohen & Steers, Inc.
Dec 10, 2025, 09:05 ET 凌科藥業與美國 Formation Bio 就 LNK01006 達成獨家開發與許可協議
IND 批准，將在美國開展首次人體臨床試驗。Formation Bio 計劃於2026年上半年啟動Ⅰ期臨床試驗，進一步體現其在構建高潛力臨床資產組合方面不斷增強的實力。 LNK01006 是一款新一代 CNS 滲透性 TYK2 變構抑制劑，兼具強效、選擇性抑制 TYK2 介導的細胞因子信號傳導能力，並具備針對中樞免疫調節而優化的藥理特性。其潛在同類最佳的選擇性和 CNS 暴露水平旨在調節中樞神經系統內的免疫信號，有望干預多種與自身免疫及炎症性疾病相關的免疫反應。其獨特的藥理特徵還可用於探索以中樞或「局域免疫通路」為關鍵發病機制的多種潛在適應症。 「該資產是我們『Known
More news about: 凌科藥業
Dec 10, 2025, 09:05 ET Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
assets.LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate
More news about: Lynk Pharmaceuticals Co., Ltd.
Dec 10, 2025, 09:00 ET Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
assets.LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate
More news about: Formation Bio
Dec 09, 2025, 08:42 ET Mercury Bio Announces Appointment of Casey Perkins as Vice President of Corporate Strategy & Business Development
Mercury Bio, a company advancing intracellular delivery for central nervous system (CNS) therapeutics through its proprietary yEV™ platform, is pleased to announce the appointment of Cassandra "Casey" Perkins as Vice President of Corporate
More news about: Mercury Bio Inc.
Dec 09, 2025, 08:00 ET Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
medicine and Adasuve®, will be eliminated, delivering immediate cost savings and enhancing overall deal economics.In addition, two promising CNS pipeline assets targeting Parkinson's disease and Cyclic Vomiting Syndrome (CVS), both at Phase 2 clinical stage, will be integrated into the Company's
More news about: Lee's Pharmaceutical Holdings Limited
Dec 09, 2025, 06:00 ET Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)
clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Dec 08, 2025, 16:24 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for November 2025
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $91.9 billion as of November 30, 2025, an increase of $1.3 billion from assets under management
More news about: Cohen & Steers, Inc.
Dec 08, 2025, 13:00 ET Moutai Returns to its Origin of World Fame, 110 Years from its Debut on Panama Expo
chapter.Media ContactDIAMOND HONG,INC. Address: 211-239 41st Street, Brooklyn, New York 11232 U.S.A.Tel: 001-9178683391CNS ENTERPRISES,INC. Address: 7709 Industry Ave., Pico Rivera, Ca 90660, U.S.A.Tel: 001-3109258482D & D LIQUOR AND WINE LLC Address:
More news about: Moutai
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
(Sumitomo Pharma Canada, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With several marketed products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage investigational assets, we aim to accelerate
More news about: Sumitomo Pharma America
Dec 08, 2025, 10:00 ET Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond
potential to redefine treatment for diseases caused by pathogenic multimeric proteins. Together with Qiming, we will expand our expertise in TPD and CNS drug development, accelerate our pipeline toward clinical proof-of-concept, and deliver on our mission to help patients with limited treatment options." Dr.
More news about: Convergen
Dec 08, 2025, 08:30 ET Cohen & Steers Named a "Best Place to Work in Money Management" by Pensions & Investments for Sixth Consecutive Year
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that it has been named as one of the "Best Places to Work in Money Management" for the sixth consecutive year by Pensions & Investments,
More news about: Cohen & Steers, Inc.
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
Brain Sci. 2020;10(2):107.7 Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.8 Leonard H, et al. CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol.
More news about: UCB
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
Epigenetics Market: The epigenetics market is segmented by product (instruments, reagents & kits), application (oncology, neurology & CNS disorders, metabolic diseases, autoimmune diseases), technology (dna methylation analysis, histone modification-acetylation, methylation), and geography
More news about: Mordor Intelligence Private Limited
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB